{
    "patients": [
    {
        "id": "2",
        "title": "P.L.",
        "age": "61",
        "file": "patient-002.xml",
        "progType": "Recurrence",
        "timeValue":1,
        "prog": "&le;12 Months<sup>*</sup>",
        "siteValue": 2,
        "loc": "Liver",
        "symp": "Mild/Moderate",
        "symptomValue":1,
        "image": { "src": "images/profiles/02.png" },
        "summary": "<ul><li>61 years of age</li><li>Recurrence &le;12 months postadjuvant therapy</li><li>Liver metastases</li><li>Mild/moderate symptoms</li></ul>",
        "banner": "<b><span>25.8<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had liver<br>metastases at baseline.</b><sup>1,‡</sup>",
        "status": {
            "row": [
                "Woman aged 61 years with a history of breast cancer",
            "Patient completed 5 years of adjuvant hormonal therapy (HT) (tamoxifen) 7 months ago",
            "Patient presents with moderate fatigue and mild right abdominal&nbsp;pain",
            "Physical examination reveals right upper quadrant (RUQ) tenderness",
            "ECOG<sup>§</sup> Performance Status: 1"
                ]
        },
        "imaging": { "row": "Bone scan, brain magnetic resonance imaging (MRI), and chest/pelvic/abdominal computed tomography (CT) scans show three 1- to 2-cm masses in liver (1 in left hepatic lobe, 2 in right hepatic lobe)" },
        "testing": {
            "row": [
                "Liver mass biopsy confirms metastatic disease with estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal growth factor receptor-2 (HER2) negative status with pathology consistent with primary tumor",
            "Laboratory values:<ul><li class=\"dash\">Hemoglobin: 11.5 mg/dL</li><li class=\"dash\">Elevated cancer antigen CA 27.29: 175 U/mL</li><li class=\"dash\">Normal liver function tests</li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence during or within 12 months of completing adjuvant hormonal therapy (tamoxifen).<br>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>1</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group."
                ]
        },
        "references": {
            "row": [
                "Data on File, 1390903. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600."
                                                                                                                                                                                                                                                                                  ]
        }
    },
    {
        "id": "3",
        "title": "M.K.",
        "age": "72",
        "file": "patient-003.xml",
        "progType": "Progression",
        "timeValue":2,
        "prog": "&gt;12 Months<sup>*</sup>",
        "siteValue": 2,
        "loc": "Liver",
        "symp": "Asymptomatic",
        "symptomValue":2,
        "image": { "src": "images/profiles/03.png" },
        "banner": "<b><span>25.8<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had liver<br/>metastases at baseline.</b><sup>1,‡</sup>",
        "summary": "<ul><li>72 years of age</li><li>Recurrence &gt;12 months after completion of adjuvant therapy</li><li>Liver metastases</li><li>Asymptomatic</li></ul>",
        "status": {
            "row": [
                "Woman aged 72 years with a history of breast cancer and&nbsp;osteoporosis",
            "Patient fell; chest radiograph ordered to rule out rib fracture",
            "Radiograph revealed few ill-defined lesions in the lung 3 years after completion of adjuvant hormonal therapy (HT) (tamoxifen)",
            "Workup for metastatic disease revealed liver masses, which were confirmed to be malignant",
            "Tamoxifen started and patient progressed 4 months later",
            "ECOG<sup>§</sup> Performance Status: 2"
                ]
        },
        "imaging": {
            "row": [
                "Computed tomography (CT) scan reveals 2 liver masses and lung lesions consistent with benign calcified granulomas",
            "Bone scan/positron emission tomography(PET) scan is negative for metastatic disease in bone",
            "No evidence of other metastatic disease"
                ]
        },
        "testing": {
            "row": [
                "Liver mass biopsy confirms estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal <br />growth factor receptor-2 (HER2) negative status, with <br />pathology consistent with primary tumor",
            "Laboratory values:<ul><li class=\"dash\">Elevated cancer antigen CA 27.29: 73 U/mL</li><li class=\"dash\">Normal liver function tests</li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence >12 months after completion of adjuvant hormonal therapy (tamoxifen) and progression<br /><div class=\"adjustRight\">after hormonal therapy (tamoxifen) for advanced disease.</div>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>1</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group."
                ]
        },
        "references": {
            "row": [
                "Data on File, 1390903. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600."
                                                                                                                                                                                                                                                                                  ]
        }
    },
    {
        "id": "4",
        "title": "G.A.",
        "age": "61",
        "file": "patient-004.xml",
        "progType": "Recurrence",
        "prog": "&le;12 Months<sup>*</sup>",
        "siteValue": 2,
        "loc": "Lung",
        "symp": "Asymptomatic",
        "symptomValue":2,
        "image": { "src": "images/profiles/04.png" },
        "banner": "<b><span>32.3<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had lung<br/>metastases at baseline.</b><sup>1,‡</sup>",
        "summary": "<ul><li>61 years of age</li><li>Recurrence &le;12 months postadjuvant therapy</li><li>Lung metastases</li><li>Asymptomatic</li></ul>",
        "status": {
            "row": [
                "Woman aged 61 years with a history of breast cancer",
            "Patient completed 5 years of adjuvant hormonal therapy (HT) (tamoxifen) 10 months ago",
            "Patient hospitalized with uncomplicated myocardial infarction<ul><li class=\"dash\">Chest x-ray reveals small pleural effusion in left lung</li></ul>",
            "ECOG<sup>§</sup> Performance Status: 1"
                ]
        },
        "imaging": { "row": "Bone scan, brain magnetic resonance imaging (MRI), and chest/pelvic/abdominal computed tomography (CT) scans show small pleural effusion in left lung with no other sites of disease; bone scan negative" },
        "testing": {
            "row": [
                "Thoracentesis:<ul><li class=\"dash\">Cytology shows malignant cells</li><li class=\"dash\">Estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal growth factor receptor-2 (HER2) negative status</li></ul>",
            "Laboratory values:<ul><li class=\"dash\">Elevated cancer antigen CA 27.29: 60 U/mL</li><li class=\"dash\">Normal liver function tests</li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence during or within 12 months of completing adjuvant hormonal therapy (tamoxifen).<br>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>1</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group."
                ]
        },
        "references": {
            "row": [
                "Data on File, 1390903. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600."
                                                                                                                                                                                                                                                                                  ]
        }
    },
    {
        "id": "5",
        "title": "N.L.",
        "age": "66",
        "file": "patient-005.xml",
        "progType":"Progression",
        "timeValue":2,
        "prog": "&gt;12 Months<sup>*</sup>",
        "siteValue": 2,
        "loc": "Lung",
        "symp": "Mild/Moderate",
        "symptomValue":1,
        "image": { "src": "images/profiles/05.png" },
        "banner": "<b><span>32.3<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had lung<br/>metastases at baseline.</b><sup>1,‡</sup>",
        "summary": "<ul><li>66 years of age</li><li>Recurrence &gt;12 months after completion of adjuvant therapy</li><li>Lung metastases</li><li>Mild/moderate symptoms</li></ul>",
        "status": {
            "row": [
                "Woman 66 years of age with a history of breast cancer",
            "Patient completed adjuvant hormonal therapy (HT) <br />(tamoxifen) 13&nbsp;months ago",
            "Diagnosed with pneumonia; showed clinical improvement; infiltrate cleared on x-ray, but there were persistent bilateral nodules<ul><li class=\"dash\">Biopsy of lung nodule confirmed metastases</li></ul>",
            "Tamoxifen started and patient progressed 5 months later",
            "ECOG<sup>§</sup> Performance Status: 1"
                ]
        },
        "imaging": {
            "row": [
                "Chest x-ray reveals suspicious bilateral 1- to 2-cm nodules",
            "Chest/pelvic/abdominal computed tomography (CT) scans, brain magnetic resonance imaging (MRI), and bone scan indicate lung nodules with no other sites of disease"
                ]
        },
        "testing": {
            "row": [
                "Biopsy of lung nodule confirms estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal growth factor receptor-2 (HER2) negative status",
            "Laboratory values:<ul><li class=\"dash\">Elevated cancer antigen CA 27.29: 57 U/mL</li><li class=\"dash\">Normal liver function tests</li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence >12 months after completion of adjuvant hormonal therapy (tamoxifen) and progression<br /><div class=\"adjustRight\">after hormonal therapy (tamoxifen) for advanced disease.</div>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>1</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group."
                ]
        },
        "references": {
            "row": [
                "Data on File, 1390903. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600."
                                                                                                                                                                                                                                                                                  ]
        }
    },
    {
        "id": "6",
        "title": "C.P.",
        "age": "72",
        "file": "patient-006.xml",
        "progType": "Recurrence",
        "timeValue":1,
        "prog": "&le;12 Months<sup>*</sup>",
        "siteValue": 1,
        "loc": "Bone",
        "symp": "Asymptomatic",
        "symptomValue":2,
        "image": { "src": "images/profiles/06.png" },
        "summary": "<ul><li>72 years of age</li><li>Recurrence &le;12 months postadjuvant therapy</li><li>Bone metastases</li><li>Asymptomatic</li></ul>",
        "banner": "<b><span>22.3<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had bone-only<br/>metastases at baseline.</b><sup>1,‡</sup>",
        "status": {
            "row": [
                "Asymptomatic woman aged 72 years with a history of breast cancer completed 5 years of adjuvant hormonal therapy (HT) (tamoxifen) 9&nbsp;months ago",
            "Bone metastases (femur) found<ul><li class=\"dash\">Patient falls off bicycle and fractures left femur. During surgical repair (open reduction and internal fixation) of femur, fracture is discovered to be pathologic</li></ul>",
            "ECOG<sup>§</sup> Performance Status: 0"
                ]
        },
        "imaging": {
            "row": [
                "Radionuclide bone scan, brain magnetic resonance imaging (MRI), chest x-ray, and chest/pelvic/abdominal computed tomography (CT) scans show mixed osteolytic and osteoblastic lesions in left femur ",
            "No evidence of other metastatic disease"
                ]
        },
        "testing": {
            "row": [
                "Biopsy of bone tissue confirms metastatic disease with estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal growth factor receptor-2 (HER2) negative status, with pathology consistent with primary tumor",
            "Laboratory values:<ul><li class=\"dash\">Elevated cancer antigen CA 27.29: 82 U/mL</li><li class=\"dash\">Normal liver function tests</li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence during or within 12 months of completing adjuvant hormonal therapy (tamoxifen).<br>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>1</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group."
                ]
        },
        "references": {
            "row": [
                "Data on File, 1196503. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600."
                                                                                                                                                                                                                                                                                  ]
        }
    },
    {
        "id": "7",
        "title": "S.M.",
        "age": "61",
        "file": "patient-007.xml",
        "progType": "Progression",
        "timeValue":2,
        "prog": "&gt;12 Months<sup>*</sup>",
        "siteValue": 1,
        "loc": "Bone",
        "symp": "Mild/Moderate",
        "symptomValue":1,
        "image": { "src": "images/profiles/07.png" },
        "banner": "<b><span>22.3<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had bone-only<br/>metastases at baseline.</b><sup>1,‡</sup>",
        "summary": "<ul><li>61 years of age</li><li>Recurrence &gt;12 months after completion of adjuvant therapy</li><li>Bone metastases</li><li>Mild/moderate symptoms</li></ul>",
        "status": {
            "row": [
                "Woman aged 61 years with a history of breast cancer presents with back pain 14 months after completion of adjuvant hormonal therapy (HT) (tamoxifen)",
            "Lumbar spine magnetic resonance imaging (MRI) confirmed&nbsp;metastases",
            "Tamoxifen started and patient progressed 4 months later",
            "ECOG<sup>§</sup> Performance Status: 1"
                ]
        },
        "imaging": {
            "row": [
                "Bone scan reveals abnormal uptake in lumbar spine and ribs",
            "Chest x-ray and chest/pelvic/abdominal computed tomography (CT) scans reveal diffuse metastases in lumbar spine and ribs with no signs of any impending pathologic fractures",
            "MRI of spine confirms findings of CT and indicates that impending cord compression is unlikely",
            "No evidence of other metastatic disease"
                ]
        },
        "testing": {
            "row": [
                "Needle aspiration biopsy of rib confirms abnormality. Estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal growth factor receptor-2 (HER2) negative status with pathology consistent with primary tumor",
            "Laboratory values:<ul><li class=\"dash\">Elevated cancer antigen CA 27.29: 78 U/mL </li><li class=\"dash\">Normal liver function tests</li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence >12 months after completion of adjuvant hormonal therapy (tamoxifen) and progression<br /><div class=\"adjustRight\">after hormonal therapy (tamoxifen) for advanced disease.</div>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>1</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group."
                ]
        },
        "references": {
            "row": [
                "Data on File, 1196503. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600."
                                                                                                                                                                                                                                                                                  ]
        }
    },
    {
        "id": "9",
        "title": "H.W.",
        "age": "68",
        "file": "patient-009.xml",
        "progType": "Recurrence",
        "timeValue":1,
        "prog": "&le;12 Months<sup>*</sup>",
        "siteValue": 2,
        "loc": "Lung and Liver",
        "symp": "Asymptomatic",
        "symptomValue":2,
        "image": { "src": "images/profiles/09.png" },
        "banner": "<b><span>32.3<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had lung<br/>metastases at baseline.</b><sup>1,‡</sup>",
        "summary": "<ul><li>68 years of age</li><li>Recurrence &le;12 months postadjuvant therapy</li><li>Lung and liver metastases</li><li>Asymptomatic</li></ul>",
        "status": {
            "row": [
                "Woman aged 68 years with a history of breast cancer",
            "Patient completed 5 years of adjuvant hormonal therapy (HT) (tamoxifen) 7 months ago",
            "Patient is on a statin for hypercholesterolemia",
            "On a routine follow-up visit, her alkaline phosphatase was noted to be elevated and a workup was ordered",
            "ECOG<sup>§</sup> Performance Status: 0"
                ]
        },
        "imaging": {
            "row": [
                "Ultrasound of liver shows 2 masses, each approximately 2 cm",
            "Bone scan, brain magnetic resonance imaging (MRI), chest x-ray, and chest/pelvic/abdominal computed tomography (CT) scans reveal 4 nodules in left lung, varying in size between 1.6 and <br />3.0 cm, and the 2 masses in liver",
            "No evidence of other metastatic disease"
                ]
        },
        "testing": {
            "row": [
                "Liver mass and lung nodule biopsies confirm metastatic disease with estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal growth factor receptor-2 (HER2) negative status with pathology consistent with primary tumor",
            "Laboratory values:<ul><li class=\"dash\">Elevated cancer antigen CA 27.29: 192 U/mL </li><li class=\"dash\">Elevated alkaline phosphatase</li><li class=\"dash\">Other liver function tests normal</li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence during or within 12 months of completing adjuvant hormonal therapy (tamoxifen).<br>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>1</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group."
                ]
        },
        "references": {
            "row": [
                "Data on File, 1390903. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600."
                                                                                                                                                                                                                                                                                  ]
        }
    },
    {
        "id": "10",
        "title": "E.B.",
        "age": "58",
        "file": "patient-010.xml",
        "progType": "Progression",
        "timeValue":2,
        "prog": "&gt;12 Months<sup>*</sup>",
        "siteValue": 2,
        "loc": "Lung and Liver",
        "symp": "Mild/Moderate",
        "symptomValue":1,
        "image": { "src": "images/profiles/10.png" },
        "banner": "<b><span>54.8<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had any visceral disease at baseline.</b><sup>1,‡</sup>",
        "summary": "<ul><li>58 years of age</li><li>Recurrence &gt;12 months after completion of adjuvant therapy</li><li>Lung and liver metastases</li><li>Mild/moderate symptoms</li></ul>",
        "status": {
            "row": [
                "58-year-old patient with a history of breast cancer",
            "Patient had completed 5 years of adjuvant hormonal therapy (HT)&nbsp;(tamoxifen)",
            "At 20 months after completion of therapy, patient presented with mild/moderate cough (cough from nasopharyngitis, <br />which later&nbsp;resolved)",
            "Chest scan showed small lung nodule (0.3 cm) in the right central&nbsp;lung<ul><li class=\"dash\">Lung cancer metastases confirmed via biopsy</li></ul>",
            "Tamoxifen started and patient progressed 10 months later",
            "ECOG<sup>§</sup> Performance Status: 0"
                ]
        },
        "imaging": {
            "row": [
                "Bone scan, chest/pelvic/abdominal computed tomography (CT) scans, and chest x-rays are performed ",
            "Imaging reveals 1 nodule (0.8 cm) in the right central lung; solitary, 1.2-cm nodule in left lung; 1 mass (1.1 cm) in liver"
                ]
        },
        "testing": {
            "row": [
                "Biopsy of the liver mass confirms estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal growth factor receptor-2 (HER2) negative status, with pathology consistent with primary tumor ",
            "Laboratory values: <ul><li class=\"dash\">Elevated cancer antigen CA 27.29: 75 U/mL </li><li class=\"dash\">Normal liver function tests</li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence >12 months after completion of adjuvant hormonal therapy (tamoxifen) and progression<br /><div class=\"adjustRight\">after hormonal therapy (tamoxifen) for advanced disease.</div>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>3</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group."
                ]
        },
        "references": {
            "row": [
                "Data on File, 1196503. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600.",
            "Data on File, 1390903. AstraZeneca Pharmaceuticals LP."
                                                                    ]
        }
    },
    {
        "id": "11",
        "title": "B.M.",
        "age": "67",
        "file": "patient-011.xml",
        "progType": "Recurrence",
        "timeValue":1,
        "prog": "&le;12 Months<sup>*</sup>",
        "siteValue": 3,
        "loc": "Liver and Bone",
        "symp": "Asymptomatic",
        "symptomValue":2,
        "image": { "src": "images/profiles/11.png" },
        "banner": "<b><span>54.8<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had anyvisceral disease at baseline.</b><sup>1,‡</sup>",
        "summary": "<ul><li>67 years of age</li><li>Recurrence &le;12 months postadjuvant therapy</li><li>Liver and bone metastases</li><li>Asymptomatic</li></ul>",
        "status": {
            "row": [
                "Woman aged 67 years with a history of breast cancer ",
            "Patient completed 5 years of adjuvant hormonal therapy (HT) (tamoxifen) 8.5 months ago",
            "Patient is taking a statin for hypercholesterolemia",
            "ECOG<sup>§</sup> Performance Status: 0"
                ]
        },
        "imaging": {
            "row": [
                "Bone scan, brain magnetic resonance imaging (MRI), chest/pelvic/abdominal computed tomography (CT) scans, and <br />x-rays are performed",
            "CT scan shows 3 distinct, 1- to 2-cm masses in the right lobe of the&nbsp;liver",
            "X-rays reveal several small lucencies in the skull and right femur; bone scan shows several areas of uptake in skull and femur"
                ]
        },
        "testing": {
            "row": [
                "Biopsy of the liver masses confirms metastatic disease with estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal growth factor receptor-2 (HER2) negative status<br />with pathology consistent with primary tumor",
            "Laboratory values:<ul><li class=\"dash\">Results of routine evaluation show abnormal liver function tests thought to be due to statin therapy<ul><li class=\"dash square\">Alkaline phosphatase (ALP): 190 IU/L</li><li class=\"dash square\">Aspartate transaminase (AST): 75 IU/L</li><li class=\"dash square\">Alanine transaminase (ALT): 81 IU/L </li><li class=\"dash square\">Bilirubin: 0.9 mg/dL</li></ul></li><li class=\"dash\">Elevated cancer antigen CA 27.29: 58 U/mL </li></ul>"
                                                                                                                                                                                                                                                                                                                                                           ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence during or within 12 months of completing adjuvant hormonal therapy (tamoxifen).<br>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>3</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group."
                ]
        },
        "references": {
            "row": [
                "Data on File, 1196503. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600.",
            "Data on File, 1390903. AstraZeneca Pharmaceuticals LP."
                                                                    ]
        }
    },
    {
        "id": "12",
        "title": "C.D.",
        "age": "64",
        "file": "patient-012.xml",
        "progType": "Recurrence",
        "timeValue":1,
        "prog": "&le;12 Months<sup>*</sup>",
        "siteValue": 3,
        "loc": "Liver and Bone",
        "symp": "Mild/Moderate",
        "symptomValue":1,
        "image": { "src": "images/profiles/12.png" },
        "banner": "<b><span>54.8<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had anyvisceral disease at baseline.</b><sup>1,‡</sup>",
        "summary": "<ul><li>64 years of age</li><li>Recurrence &le;12 months postadjuvant therapy</li><li>Liver and bone metastases</li><li>Mild/moderate symptoms</li></ul>",
        "status": {
            "row": [
                "Woman aged 64 years with a history of breast cancer",
            "Patient presents with pain in the lumbar spine 10 months after completion of adjuvant hormonal therapy (HT) (tamoxifen)",
            "ECOG<sup>§</sup> Performance Status: 1"
                ]
        },
        "imaging": {
            "row": [
                "Bone scan, brain magnetic resonance imaging (MRI), and chest/pelvic/abdominal computed tomography (CT) scans are&nbsp;performed",
            "Bone scan reveals 3 areas of abnormal uptake in the lumbar spine. Lumbar MRI reveals lytic/blastic lesions in the lumbar spine with no compression fracture or impending cord impingement",
            "CT scan and liver MRI reveal a solitary 1.5-cm mass in right hepatic lobe; no evidence of biliary dilatation"
                ]
        },
        "testing": {
            "row": [
                "Liver aspiration confirms estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal growth factor receptor-2 (HER2) negative status with pathology consistent with the primary tumor",
            "Laboratory values:<ul><li class=\"dash\">Elevated cancer antigen CA 27.29: 65 U/mL </li><li class=\"dash\">Normal liver function tests</li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence during or within 12 months of completing adjuvant hormonal therapy (tamoxifen).<br>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>3</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group."
                ]
        },
        "references": {
            "row": [
                "Data on File, 1196503. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600.",
            "Data on File, 1390903. AstraZeneca Pharmaceuticals LP."
                                                                    ]
        }
    },
    {
        "id": "13",
        "title": "T.H.",
        "age": "64",
        "file": "patient-013.xml",
        "progType":"Progression",
        "timeValue":2,
        "prog": "&gt;12 Months<sup>*</sup>",
        "siteValue": 3,
        "loc": "Lung and Bone",
        "symp": "Asymptomatic",
        "symptomValue":2,
        "image": { "src": "images/profiles/13.png" },
        "banner": "<b><span>54.8<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had anyvisceral disease at baseline.</b><sup>1,‡</sup>",
        "summary": "<ul><li>64 years of age</li><li>Recurrence &gt;12 months after completion of adjuvant therapy</li><li>Lung and bone metastases</li><li>Asymptomatic</li></ul>",
        "status": {
            "row": [
                "Woman aged 64 years with a history of breast cancer",
            "Patient completed 5 years of adjuvant hormonal therapy (HT) (tamoxifen) 15 months ago",
            "Patient was a smoker with a 50 pack/year history",
            "Patient was found to have an abnormality on a chest radiograph performed as part of a routine employment <br />physical<ul><li class=\"dash\">Subsequent chest x-ray and computed tomography (CT) <br />scan revealed a pleural effusion one-third of the way up <br />the left hemithorax and 2 small nodules in the right <br />upper lung (each&nbsp;1.2&nbsp;cm)<sup>§</sup></li><li class=\"dash\">Biopsy of lung nodule confirmed metastases</li></ul>",
            "Tamoxifen started and patient progressed 8 months later",
            "ECOG<sup>||</sup> Performance Status: 0"
                ]
        },
        "imaging": {
            "row": [
                "Bone scan, brain magnetic resonance imaging (MRI), and CT scans of the pelvis and abdomen are performed",
            "Bone scan reveals uptake in L1, L3, and L4"
                ]
        },
        "testing": {
            "row": [
                "Thoracentesis:<ul><li class=\"dash\">Cytology shows malignant cells with estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal growth factor receptor-2 (HER2) negative status</li></ul>",
            "Laboratory values:<ul><li class=\"dash\">Routine chemistries are normal</li><li class=\"dash\">Elevated cancer antigen CA 27.29: 74 U/mL</li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence >12 months after completion of adjuvant hormonal therapy (tamoxifen) and progression<br /><div class=\"adjustRight\">after hormonal therapy (tamoxifen) for advanced disease.</div>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>3</sup></div>",
            "<sup>§</sup>This image is from a case study co-authored by Andetta Hunsaker, MD, and is reprinted<br><div class=\"adjustRight\">with permission from the Brigham and Women's Hospital Department of Radiology.</div>",
            "<sup>||</sup>Eastern Cooperative Oncology Group."
                ]
        },
        "references": {
            "row": [
                "Data on File, 1196503. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600.",
            "Data on File, 1390903. AstraZeneca Pharmaceuticals LP."
                                                                    ]
        }
    },
    {
        "id": "14",
        "title": "Z.P.",
        "age": "62",
        "file": "patient-014.xml",
        "progType":"Progression",
        "timeValue":2,
        "prog": "&gt;12 Months<sup>*</sup>",
        "siteValue": 3,
        "loc": "Lung and Bone",
        "symp": "Mild/Moderate",
        "symptomValue":1,
        "image": { "src": "images/profiles/14.png" },
        "banner": "<b><span>60.3<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patientswere &lt;65 years <br/>of age.</b><sup>1</sup>",
        "summary": "<ul><li>62 years of age</li><li>Recurrence &gt;12 months after completion of adjuvant therapy</li><li>Lung and bone metastases</li><li>Mild/moderate symptoms</li></ul>",
        "status": {
            "row": [
                "Woman aged 62 years with a history of breast cancer ",
            "Patient presents with rib pain despite having done well for 18 months after completion of 5 years of adjuvant hormonal therapy (HT) (tamoxifen)<ul><li class=\"dash\">Bone scan and subsequent biopsy confirmed metastases</li></ul>",
            "Tamoxifen started and patient progressed 5 months later",
            "ECOG<sup>‡</sup> Performance Status: 1"
                ]
        },
        "imaging": {
            "row": [
                "Bone scan, brain magnetic resonance imaging (MRI), and chest/pelvic/abdominal computed tomography (CT) scans show<br />new nodules in left lung and several lytic lesions in ribs and lumbar&nbsp;vertebra",
            "No evidence of other metastatic disease"
                ]
        },
        "testing": {
            "row": [
                "Biopsy of lung nodule reveals estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal growth factor receptor-2 (HER2) negative status, with pathology consistent with primary tumor",
            "Laboratory values:<ul><li class=\"dash\">Elevated cancer antigen CA 27.29: 62 U/mL</li><li class=\"dash\">Normal liver function tests</li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence >12 months after completion of adjuvant hormonal therapy (tamoxifen) and progression<br /><div class=\"adjustRight\">after hormonal therapy (tamoxifen) for advanced disease.</div>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Eastern Cooperative Oncology Group."
                ]
        },
        "references": {
            "row": [
                "Data on File, 1198501. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600."
                                                                                                                                                                                                                                                                                  ]
        }
    },
    {
        "id": "16",
        "title": "A.M.",
        "age": "53",
        "file": "patient-016.xml",
        "progType":"Progression",
        "timeValue":2,
        "prog": "&gt;12 Months<sup>*</sup>",
        "siteValue": 3,
        "loc": "Locoregional Lymph Nodes and Lung",
        "symp": "Asymptomatic",
        "symptomValue":2,
        "image": { "src": "images/profiles/16.png" },
        "banner": "<b><span>54.8<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had anyvisceral disease at baseline.</b><sup>1,‡</sup>",
        "summary": "<ul><li>53 years of age</li><li>Recurrence &gt;12 months after completion of adjuvant therapy</li><li>Locoregional recurrence and lung metastases</li><li>Asymptomatic</li></ul>",
        "status": {
            "row": [
                "Woman aged 53 years with a history of breast cancer",
            "Patient presented with a palpable mass in the ipsilateral axilla detected during routine clinical examination 14 months after completion of adjuvant hormonal therapy (HT) (tamoxifen)<ul><li class=\"dash\">Biopsy of axillary mass confirmed malignancy</li></ul>",
            "Tamoxifen started and patient progressed 4 months later",
            "ECOG<sup>§</sup> Performance Status: 0"
                ]
        },
        "imaging": {
            "row": [
                "Bone scan, chest/pelvic/abdominal computed tomography (CT) scans, and chest x-ray are performed",
            "Imaging reveals 1 nodule in the peripheral right lung"
                ]
        },
        "testing": {
            "row": [
                "Biopsies of the axillary mass show estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal growth factor receptor-2 (HER2) negative status with pathology consistent with the primary tumor",
            "Laboratory values:<ul><li class=\"dash\">Elevated cancer antigen CA 27.29: 80 U/mL </li><li class=\"dash\">Normal liver function tests</li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence >12 months after completion of adjuvant hormonal therapy (tamoxifen) and progression<br /><div class=\"adjustRight\">after hormonal therapy (tamoxifen) for advanced disease.</div>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>3</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group."
                ]
        },
        "references": {
            "row": [
                "Data on File, 1196503. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600.",
            "Data on File, 1390903. AstraZeneca Pharmaceuticals LP."
                                                                    ]
        }
    },
    {
        "id": "17",
        "title": "D.G.",
        "age": "68",
        "file": "patient-017.xml",
        "progType":"Progression",
        "timeValue":2,
        "prog": "&gt;12 Months<sup>*</sup>",
        "siteValue": 3,
        "loc": "Skin/Soft Tissue and Pleura",
        "symp": "Mild/Moderate",
        "symptomValue":1,
        "image": { "src": "images/profiles/17.png" },
        "banner": "<b><span>10.9<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had pleura<br/>metastases at baseline.</b><sup>1,‡</sup>",
        "summary": "<ul><li>68 years of age</li><li>Recurrence &gt;12 months after completion of adjuvant therapy</li><li>Skin/soft tissue and pleura metastases</li><li>Mild/moderate symptoms</li></ul>",
        "status": {
            "row": [
                "Woman aged 68 years with a history of breast cancer",
            "Patient presented with a 0.5-cm mass in skin 10 years after completion of adjuvant hormonal therapy (HT) (tamoxifen)<ul><li class=\"dash\">Biopsy confirmed metastases</li></ul>",
            "Tamoxifen started and patient progressed 9 months later",
            "ECOG<sup>§</sup> Performance Status: 1"
                ]
        },
        "imaging": {
            "row": [
                "Bone scan is negative",
            "Chest x-ray and chest/pelvic/abdominal computed tomography (CT) scans reveal left pleural effusion",
            "No evidence of other metastatic disease"
                ]
        },
        "testing": {
            "row": [
                "Skin mass biopsy confirms estrogen receptor (ER)+/<br />progesterone receptor (PgR)+, human epidermal growth <br />factor receptor-2 (HER2) negative status with pathology <br />consistent with primary tumor",
            "Thoracentesis:<ul><li class=\"dash\">Cytology shows ER+/PgR+/HER2- malignant cells</li></ul>",
            "Laboratory values:<ul><li class=\"dash\">Elevated cancer antigen CA 27.29: 60 U/mL </li><li class=\"dash\">Normal liver function tests</li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence >12 months after completion of adjuvant hormonal therapy (tamoxifen) and progression<br /><div class=\"adjustRight\">after hormonal therapy (tamoxifen) for advanced disease.</div>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>1</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group."
                ]
        },
        "references": {
            "row": [
                "Data on File, 1390903. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600."
                                                                                                                                                                                                                                                                                  ]
        }
    },
    {
        "id": "18",
        "title": "R.C.",
        "age": "61",
        "file": "patient-018.xml",
        "progType": "Recurrence",
        "timeValue":1,
        "prog": "&le;12 Months<sup>*</sup>",
        "siteValue": 3,
        "loc": "Lung and Soft Tissue",
        "symp": "Mild/Moderate",
        "symptomValue":1,
        "image": { "src": "images/profiles/18.png" },
        "banner": "<b><span>54.8<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had anyvisceral disease at baseline.</b><sup>1,‡</sup>",
        "summary": "<ul><li>61 years of age</li><li>Recurrence &le;12 months postadjuvant therapy</li><li>Lung and soft-tissue metastases</li><li>Mild/moderate symptoms</li></ul>",
        "status": {
            "row": [
                "Woman aged 61 years with a history of breast cancer ",
            "Patient completed 5 years of adjuvant hormonal therapy (HT) (tamoxifen) 6 months ago",
            "Patient complains of minimal fullness in lower right neck",
            "ECOG<sup>§</sup> Performance Status: 1"
                ]
        },
        "imaging": {
            "row": [
                "Bone scan, brain magnetic resonance imaging (MRI), and chest/pelvic/abdominal computed tomography (CT) scans reveal multiple new bilateral nodules in lungs ",
            "No evidence of other metastatic disease "
                ]
        },
        "testing": {
            "row": [
                "Biopsy of palpable right supraclavicular node confirms estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal growth factor receptor-2 (HER2) negative status, with pathology consistent with primary tumor",
            "Laboratory values:<ul><li class=\"dash\">Elevated cancer antigen CA 27.29: 183 U/mL</li><li class=\"dash\">Normal liver function tests</li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence during or within 12 months of completing adjuvant hormonal therapy (tamoxifen).<br>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>3</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group."
                ]
        },
        "references": {
            "row": [
                "Data on File, 1196503. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600.",
            "Data on File, 1390903. AstraZeneca Pharmaceuticals LP."
                                                                    ]
        }
    },
    {
        "id": "19",
        "title": "S.F.",
        "age": "62",
        "file": "patient-019.xml",
        "progType": "Recurrence",
        "timeValue":1,
        "prog": "&le;12 Months<sup>*</sup>",
        "siteValue": 3,
        "loc": "Liver and Skin",
        "symp": "Asymptomatic",
        "symptomValue":2,
        "image": { "src": "images/profiles/19.png" },
        "banner": "<b><span>54.8<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had anyvisceral disease at baseline.</b><sup>1,‡</sup>",
        "summary": "<ul><li>62 years of age</li><li>Recurrence &le;12 months postadjuvant therapy</li><li>Liver and skin metastases</li><li>Asymptomatic</li></ul>",
        "status": {
            "row": [
                "Woman aged 62 years with a history of breast cancer and rheumatoid arthritis",
            "Patient presents with a 1.5-cm metastasis in skin overlying lumpectomy site detected during routine clinical examination 11 months after completion of 5 years of adjuvant hormonal therapy (HT) (tamoxifen)",
            "ECOG<sup>§</sup> Performance Status: 1"
                ]
        },
        "imaging": {
            "row": [
                "Ultrasound reveals two 1.0-cm metastases in liver",
            "Bone scan, chest/pelvic/abdominal computed tomography (CT) scans, and magnetic resonance imaging (MRI) confirm liver findings; no other sites of metastatic disease detected<sup>||</sup>",
            "Brain MRI negative"
                ]
        },
        "testing": {
            "row": [
                "Biopsies of liver and skin confirm estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal growth factor receptor-2 (HER2) negative status with pathology consistent with primary tumor",
            "Laboratory values:<ul><li class=\"dash\">Alkaline phosphatase levels slightly elevated: 190 IU/L</li><li class=\"dash\">Other liver function tests normal</li><li class=\"dash\">Elevated cancer antigen CA 27.29: 260 U/mL </li><li class=\"dash\">Carcinoembryonic antigen (CEA): 5.5 ng/mL </li></ul>"
                                                                                                                                                                                                                                                                                                 ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence during or within 12 months of completing adjuvant hormonal therapy (tamoxifen).<br>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>3</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group.<br>",
            "<sup>||</sup>Reprinted, with permission, from <em>Radiology</em> 2006;239:122-130. © Radiological Society of<br><div class=\"adjustRight\">North America.</div>"
                ]
        },
        "references": {
            "row": [
                "Data on File, 1196503. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600.",
            "Data on File, 1390903. AstraZeneca Pharmaceuticals LP."
                                                                    ]
        }
    },
    {
        "id": "20",
        "title": "L.C.",
        "age": "51",
        "file": "patient-020.xml",
        "progType":"Progression",
        "timeValue":2,
        "prog": "&gt;12 Months<sup>*</sup>",
        "siteValue": 2,
        "loc": "Pleura",
        "symp": "Mild/Moderate",
        "symptomValue":1,
        "image": { "src": "images/profiles/20.png" },
        "banner": "<b><span>10.9<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had pleura<br/>metastases at baseline.</b><sup>1,‡</sup>",
        "summary": "<ul><li>51 years of age</li><li>Recurrence &gt;12 months after completion of adjuvant therapy</li><li>Pleural effusion</li><li>Mild/moderate symptoms</li></ul>",
        "status": {
            "row": [
                "Woman aged 51 years with a history of breast cancer ",
            "Patient presented with mild shortness of breath 24 months <br />after completion of 5 years of adjuvant hormonal therapy (HT) (tamoxifen)",
            "Clinical examination revealed dullness to percussion in right lower lung field<ul><li class=\"dash\">Workup including chest x-ray and thoracentesis confirmed pleural&nbsp;metastases</li></ul>",
            "Patient admitted to difficulty remembering to take pills",
            "Tamoxifen started and patient progressed 4 months later",
            "ECOG<sup>§</sup> Performance Status: 1"
                ]
        },
        "imaging": {
            "row": [
                "Chest x-ray shows small pleural effusion on right side<sup>||</sup>",
            "Chest/pelvic/abdominal computed tomography (CT) scans are negative, except for a moderate volume pleural effusion on right&nbsp;side",
            "Bone scan and brain magnetic resonance imaging (MRI) are negative"
                ]
        },
        "testing": {
            "row": [
                "Thoracentesis:<ul><li class=\"dash\">Cytology shows malignant cells</li><li class=\"dash\">Estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal growth factor receptor-2 (HER2) negative status</li></ul>",
            "Laboratory values:<ul><li class=\"dash\">Elevated cancer antigen CA 27.29: 47 U/mL </li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence >12 months after completion of adjuvant hormonal therapy (tamoxifen) and progression<br /><div class=\"adjustRight\">after hormonal therapy (tamoxifen) for advanced disease.</div>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>1</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group.",
            "<br /><sup>||</sup>This image is reprinted with permission from the Brigham and Women's Hospital<br /><div class=\"adjustRight\">Department of Radiology.</div>"
                ]
        },
        "references": {
            "row": [
                "Data on File, 1390903. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600."
                                                                                                                                                                                                                                                                                  ]
        }
    },
    {
        "id": "21",
        "title": "K.C.",
        "age": "57",
        "file": "patient-021.xml",
        "progType":"Progression",
        "timeValue":2,
        "prog": "&gt;12 Months<sup>*</sup>",
        "siteValue": 3,
        "loc": "Distant Metastatic Lymph Nodes",
        "symp": "Asymptomatic",
        "symptomValue":2,
        "image": { "src": "images/profiles/21.png" },
        "banner": "<b><span>33.0<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had distant<br/>lymph node metastases at baseline.</b><sup>1,‡</sup>",
        "summary": "<ul><li>57 years of age</li><li>Recurrence &gt;12 months after completion of adjuvant therapy</li><li>Distant metastatic lymph nodes</li><li>Asymptomatic</li></ul>",
        "status": {
            "row": [
                "Asymptomatic woman aged 57 years with a history of breast cancer",
            "Patient completed 5 years of adjuvant hormonal therapy (HT) (tamoxifen) 22 months ago",
            "Distant metastatic lymph node found<ul><li class=\"dash\">During routine clinical exam, a palpable 1.6-cm cervical lymph node is discovered; fine-needle aspiration in office confirmed metastatic breast cancer</li></ul>",
            "Tamoxifen started and patient progressed 6 months later <br />based on surveillance scan",
            "ECOG<sup>§</sup> Performance Status: 0"
                ]
        },
        "imaging": {
            "row": [
                "Neck/chest/abdominal/pelvic computed tomography (CT) scan confirms a 2.5-cm cervical lymph node; bone scan is normal<sup>||</sup>",
            "No evidence of other metastatic disease "
                ]
        },
        "testing": {
            "row": [
                "Biopsy of the cervical lymph node confirms metastatic disease with estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal growth factor receptor-2 (HER2) negative status with pathology consistent with primary tumor",
            "Laboratory values:<ul><li class=\"dash\">Elevated cancer antigen CA 27.29: 53 U/mL </li><li class=\"dash\">Normal liver function tests </li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence >12 months after completion of adjuvant hormonal therapy (tamoxifen) and progression<br /><div class=\"adjustRight\">after hormonal therapy (tamoxifen) for advanced disease.</div>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>1</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group.",
            "<br /><sup>||</sup>Republished with permission of <em>The Journal of Oral and Maxillofacial Surgery</em>, from<br /><div class=\"adjustRight\">Staging of Head and Neck Tumors: [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission <br />Tomography Compared With Physical Examination and Conventional Imaging <br />Modalities. Sigg MB, Steinert H, Gr&auml;tz K, Hugenin P, Stoeckli S, Eyrich GK.<br /> 61:1022-1029;2003; permission conveyed through Copyright Clearance Center, Inc.</div>"
                ]
        },
        "references": {
            "row": [
                "Data on File, 1390903. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600."
                                                                                                                                                                                                                                                                                  ]
        }
    },
    {
        "id": "22",
        "title": "I.M.",
        "age": "54",
        "file": "patient-022.xml",
        "progType": "Recurrence",
        "timeValue":1,
        "prog": "&le;12 Months<sup>*</sup>",
        "siteValue": 3,
        "loc": "Locoregional Recurrence and Pleura",
        "symp": "Asymptomatic",
        "symptomValue":2,
        "image": { "src": "images/profiles/22.png" },
        "banner": "<b><span>10.9<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had pleura<br/>metastases at baseline.</b><sup>1,‡</sup>",
        "summary": "<ul><li>54 years of age</li><li>Recurrence &le;12 months postadjuvant therapy</li><li>Locoregional recurrence and pleura metastases</li><li>Asymptomatic</li></ul>",
        "status": {
            "row": [
                "Woman aged 54 years with a history of breast cancer ",
            "Patient completed 5 years of adjuvant hormonal therapy (HT) (tamoxifen) 11 months ago",
            "Patient presents with a 1.2-cm mass in the ipsilateral breast found during a routine mammogram and confirmed by breast magnetic resonance imaging (MRI)",
            "ECOG<sup>§</sup> Performance Status: 0"
                ]
        },
        "imaging": {
            "row": [
                "Bone scan, brain MRI, and computed tomography (CT) scans of the chest, pelvis, and abdomen are performed",
            "CT scan of the chest reveals a small volume pleural effusion on the left side<sup>||</sup>",
            "No evidence of other metastatic disease"
                ]
        },
        "testing": {
            "row": [
                "Biopsy of breast mass confirms metastatic disease with <br />estrogen receptor (ER)+/progesterone receptor (PgR)+, human <br />epidermal growth factor receptor-2 (HER2) negative status <br />with pathology consistent with primary tumor",
            "Thoracentesis:<ul><li class=\"dash\">Cytology shows malignant cells with ER+/PgR+, HER2- status</li></ul>",
            "Laboratory values:<ul><li class=\"dash\">Routine chemistries are normal</li><li class=\"dash\">Elevated cancer antigen CA 27.29: 44 U/mL </li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence during or within 12 months of completing adjuvant hormonal therapy (tamoxifen).<br>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br /><div class=\"adjustRight\">counted only once in that site.<sup>1</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group.<br />",
            "<sup>||</sup>With kind permission from Springer Science+Business Media: <i>Medical Oncology</i>, Systemic <br /><span class=\"adjustRight\">chemotherapy of TS-1 and cisplatin for gastric signet-ring cell carcinoma presenting as</span> <br /><span class=\"adjustRight\">cardiac tamponade, vol 25, 2008, p242, Kusaba H et al, Figure 3, © Humana Press Inc. 2007.</span>"
                ]
        },
        "references": {
            "row": [
                "Data on File, 1390903. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600."
                                                                                                                                                                                                                                                                                  ]
        }
    },
    {
        "id": "23",
        "title": "G.B.",
        "age": "60",
        "file": "patient-023.xml",
        "progType":"Progression",
        "timeValue":2,
        "prog": "&gt;12 Months<sup>*</sup>",
        "siteValue": 3,
        "loc": "Skin/Soft Tissue and Pleura",
        "symp": "Asymptomatic",
        "symptomValue":2,
        "image": { "src": "images/profiles/23.png" },
        "banner": "<b><span>14.9<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had any<br/>skin/soft-tissue metastases at baseline.</b><sup>1,‡</sup>",
        "summary": "<ul><li>60 years of age</li><li>Recurrence &gt;12 months after completion of adjuvant therapy</li><li>Skin/soft tissue and pleura metastases</li><li>Asymptomatic</li></ul>",
        "status": {
            "row": [
                "Asymptomatic woman aged 60 years with a history of breast cancer treated with a left mastectomy ",
            "Completed 5 years of adjuvant hormonal therapy (HT) (tamoxifen) 25&nbsp;months ago",
            "Skin and soft-tissue metastases found",
            "During routine clinical exam, 2 separate 0.5-cm nodules in the mastectomy scar tissue and a solitary 1.2-cm nodule in the skin of the left upper abdominal quadrant are detected; biopsy shows metastatic breast cancer",
            "Tamoxifen started and patient progressed 6 months later with identical, multiple skin lesions seen on abdomen",
            "ECOG<sup>§</sup> Performance Status: 0"
                ]
        },
        "imaging": {
            "row": [
                "Chest/abdominal/pelvic computed tomography (CT) scans and bone scan reveal a new, small-volume right pleural effusion<sup>||</sup>",
            "No evidence of other metastatic disease"
                ]
        },
        "testing": {
            "row": [
                "Thoracentesis shows malignant cells and cell block shows metastatic disease with estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal growth factor receptor-2 (HER2) negative status; pathology consistent with primary tumor",
            "Laboratory values:<ul><li class=\"dash\">Elevated cancer antigen CA 27.29: 40 U/mL</li><li class=\"dash\">Normal liver function tests</li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence >12 months after completion of adjuvant hormonal therapy (tamoxifen) and progression<br /><div class=\"adjustRight\">after hormonal therapy (tamoxifen) for advanced disease.</div>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>1</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group.",
            "<br /><sup>||</sup>Republished with permission of <em>The Internet Journal of Pulmonary Medicine</em>, from Mantle<br><div class=\"adjustRight\">Cell Lymphoma Presenting With Persistent Pleural Effusion and Severe Thrombocytopenia.<br />Papaioannou AI, Kostikas K, Tzovaras N, et al. 6(2):2006; permission conveyed through<br />Copyright Clearance Center, Inc.</div>"
                ]
        },
        "references": {
            "row": [
                "Data on File, 1390903. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600."
                                                                                                                                                                                                                                                                                  ]
        }
    },
    {
        "id": "24",
        "title": "F.T.",
        "age": "70",
        "file": "patient-024.xml",
        "progType":"Progression",
        "timeValue":2,
        "prog": "&gt;12 Months<sup>*</sup>",
        "siteValue": 1,
        "loc": "Bone",
        "symp": "Asymptomatic",
        "symptomValue":2,
        "image": { "src": "images/profiles/24.png" },
        "banner": "<b><span>22.3<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had bone-only<br/>metastases at baseline.</b><sup>1,‡</sup>",
        "summary": "<ul><li>70 years of age</li><li>Recurrence &gt;12 months after completion of adjuvant therapy</li><li>Bone metastases</li><li>Asymptomatic</li></ul>",
        "status": {
            "row": [
                "Woman aged 70 years with a history of breast cancer ",
            "Completed 5 years of adjuvant hormonal therapy (HT) (tamoxifen) 20&nbsp;months ago",
            "Woman fell resulting in evaluation of a bruised right hip; imaging showed 2 small lytic lesions to right hip<ul><li class=\"dash\">Bone metastases confirmed via bone scan and biopsy</li></ul>",
            "Tamoxifen started and patient progressed 6 months later <br />based on surveillance scan",
            "ECOG<sup>§</sup> Performance Status: 0"
                ]
        },
        "imaging": {
            "row": [
                "X-ray image of pelvic area reveals 3 small lytic lesions to right hip",
            "Chest/pelvic/abdominal computed tomography (CT) scans and bone scan confirm pelvic bone lesions, which are consistent with metastatic disease; no evidence of other metastatic disease "
                ]
        },
        "testing": {
            "row": [
                "Biopsy of bone tissue confirms metastatic disease with estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal growth factor receptor-2 (HER2) negative status; pathology consistent with primary tumor ",
            "Laboratory values:<ul><li class=\"dash\">Elevated cancer antigen CA 27.29: 84 U/mL</li><li class=\"dash\">Normal liver function tests</li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence >12 months after completion of adjuvant hormonal therapy (tamoxifen) and progression<br /><div class=\"adjustRight\">after hormonal therapy (tamoxifen) for advanced disease.</div>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>1</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group."
                ]
        },
        "references": {
            "row": [
                "Data on File, 1196503. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600."
                                                                                                                                                                                                                                                                                  ]
        }
    },
    {
        "id": "25",
        "title": "B.R.",
        "age": "64",
        "file": "patient-025.xml",
        "progType": "Recurrence",
        "timeValue":1,
        "prog": "&le;12 Months<sup>*</sup>",
        "siteValue": 1,
        "loc": "Bone",
        "symp": "Mild/Moderate",
        "symptomValue":1,
        "image": { "src": "images/profiles/25.png" },
        "banner": "<b><span>22.3<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had bone-only<br/>metastases at baseline.</b><sup>1,‡</sup>",
        "summary": "<ul><li>64 years of age</li><li>Recurrence &le;12 months postadjuvant therapy</li><li>Bone metastases</li><li>Mild/moderate symptoms</li></ul>",
        "status": {
            "row": [
                "Woman aged 64 years with a history of breast cancer presents with back pain and occasional weakness in legs 11 months after completion of 5 years of adjuvant hormonal therapy (HT) (tamoxifen)",
            "ECOG<sup>§</sup> Performance Status: 1"
                ]
        },
        "imaging": {
            "row": [
                "Radionuclide bone scan, brain/spinal magnetic resonance imaging (MRI), and chest/pelvic/abdominal computed tomography (CT) scans show spinal cord compression caused <br />by 2 lesions in the thoracic&nbsp;vertebrae",
            "No evidence of other metastatic disease"
                ]
        },
        "testing": {
            "row": [
                "Bone tissue confirms metastatic disease with estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal growth factor receptor-2 (HER2) negative status with pathology consistent with primary tumor",
            "Laboratory values:<ul><li class=\"dash\">Elevated cancer antigen CA 27.29: 80 U/mL</li><li class=\"dash\">Normal liver function tests</li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence during or within 12 months of completing adjuvant hormonal therapy (tamoxifen).<br>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>1</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group."
                ]
        },
        "references": {
            "row": [
                "Data on File, 1196503. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600."
                                                                                                                                                                                                                                                                                  ]
        }
    },
    {
        "id": "26",
        "title": "W.S.",
        "age": "61",
        "file": "patient-026.xml",
        "progType": "Recurrence",
        "timeValue":1,
        "prog": "&le;12 Months<sup>*</sup>",
        "siteValue": 1,
        "loc": "Bone",
        "symp": "Asymptomatic",
        "symptomValue":2,
        "image": { "src": "images/profiles/26.png" },
        "summary": "<ul><li>61 years of age</li><li>Recurrence &le;12 months postadjuvant therapy</li><li>Bone metastases</li><li>Asymptomatic</li></ul>",
        "banner": "<b><span>22.3<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had bone-only<br/>metastases at baseline.</b><sup>1,‡</sup>",
        "status": {
            "row": [
                "Asymptomatic woman aged 61 years with a history of breast cancer",
            "5 years of adjuvant hormonal therapy (HT) (tamoxifen) completed 3 months ago",
            "Bone metastases (right ribs) found<ul><li class=\"dash\">Patient has fall; x-ray reveals 2 small abnormalities on ribs</li><li class=\"dash\">Bone scan is suggestive of metastatic disease</li></ul>",
            "ECOG<sup>§</sup> Performance Status: 0"
                ]
        },
        "imaging": {
            "row": [
                "Chest/pelvic/abdominal computed tomography (CT) scans are consistent with abnormalities on bone scan and show 2 sclerotic lesions on right ribs",
            "No evidence of other metastatic disease"
                ]
        },
        "testing": {
            "row": [
                "<span class=\"no_bottom_padding\">Bone biopsy of rib confirms malignancy. Estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal growth factor receptor-2 (HER2) negative status, with pathology consistent with primary tumor",
            "Laboratory values:<ul><li class=\"dash\">Elevated cancer antigen CA 27.29: 79 U/mL</li><li class=\"dash\">Normal liver function tests</li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence during or within 12 months of completing adjuvant hormonal therapy (tamoxifen).<br>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>1</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group.<br>"
                ]
        },
        "references": {
            "row": [
                "Data on File, 1196503. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600."
                                                                                                                                                                                                                                                                                  ]
        }
    },
    {
        "id": "27",
        "title": "R.K.",
        "age": "71",
        "file": "patient-027.xml",
        "progType": "Recurrence",
        "timeValue":1,
        "prog": "&le;12 Months<sup>*</sup>",
        "siteValue": 1,
        "loc": "Bone",
        "symp": "Mild/Moderate",
        "symptomValue":1,
        "image": { "src": "images/profiles/27.png" },
        "banner": "<b><span>22.3<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had bone-only<br/>metastases at baseline.</b><sup>1,‡</sup>",
        "summary": "<ul><li>71 years of age</li><li>Recurrence &le;12 months postadjuvant therapy</li><li>Bone metastases</li><li>Mild/moderate symptoms</li></ul>",
        "status": {
            "row": [
                "Woman aged 71 years with a history of breast cancer",
            "Completed 5 years of adjuvant hormonal therapy (HT) (tamoxifen) 9 months ago",
            "Complains of pain in right hip and upper leg for past 6 weeks as well as fatigue; pain is dull and persistent, but unaffected by activity",
            "ECOG<sup>§</sup> Performance Status: 1"
                ]
        },
        "imaging": {
            "row": [
                "X-rays of the hip and pelvis show 3 small lytic lesions in right ilium",
            "Chest/pelvic/abdominal computed tomography (CT) scans confirm the presence of the ilial lesions but no other abnormalities are identified<sup>||</sup>",
            "Bone scan shows no evidence of other metastatic disease"
                ]
        },
        "testing": {
            "row": [
                "Bone biopsy confirms metastatic disease. Estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal growth factor receptor-2 (HER2) negative status, with pathology consistent with primary tumor",
            "Laboratory values:<ul><li class=\"dash\">Elevated cancer antigen CA 27.29: 92 U/mL</li><li class=\"dash\">Normal liver function tests</li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence during or within 12 months of completing adjuvant hormonal therapy (tamoxifen).<br>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>1</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group.<br>",
            "<sup>||</sup>Reprinted with permission from Diagnostic Imaging."
                ]
        },
        "references": {
            "row": [
                "Data on File, 1196503. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600."
                                                                                                                                                                                                                                                                                  ]
        }
    },
    {
        "id": "28",
        "title": "L.S.",
        "age": "62",
        "file": "patient-028.xml",
        "progType":"Progression",
        "timeValue":2,
        "prog": "&gt;12 Months<sup>*</sup>",
        "siteValue": 1,
        "loc": "Bone",
        "symp": "Asymptomatic",
        "symptomValue":2,
        "image": { "src": "images/profiles/28.png" },
        "banner": "<b><span>61.0<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had any bone<br/>metastases at baseline.</b><sup>1,‡</sup>",
        "summary": "<ul><li>62 years of age</li><li>Recurrence &gt;12 months after completion of adjuvant therapy</li><li>Bone metastases</li><li>Asymptomatic</li></ul>",
        "status": {
            "row": [
                "Asymptomatic woman aged 62 years with a history of breast cancer",
            "Patient had completed adjuvant hormonal therapy (HT) (tamoxifen) 18 months ago",
            "Woman was involved in auto accident and complained of shoulder and arm pain as a result; x-rays incidentally showed abnormalities of the right humerus not associated with symptoms<ul><li class=\"dash\">Magnetic resonance imaging (MRI) was highly suggestive <br />of bone metastases</li></ul>",
            "Tamoxifen was started and patient progressed 13 months later based on surveillance bone scan",
            "ECOG<sup>§</sup> Performance Status: 0"
                ]
        },
        "imaging": {
            "row": [
                "Radionuclide bone scan and MRI show progression of metastatic disease in right humerus<sup>||</sup>",
            "No evidence of other metastatic disease"
                ]
        },
        "testing": {
            "row": [
                "Biopsy of bone tissue confirms metastatic disease. Estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal growth factor receptor-2 (HER2) negative status, with pathology consistent with primary tumor",
            "Laboratory values:<ul><li class=\"dash\">Elevated cancer antigen CA 27.29: 85 U/mL</li><li class=\"dash\">Normal liver function tests</li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence >12 months after completion of adjuvant hormonal therapy (tamoxifen) and progression<br /><div class=\"adjustRight\">after hormonal therapy (tamoxifen) for advanced disease.</div>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>1</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group.<br>",
            "<sup>||</sup>From Kim SY, et al. <i>Korean J Pain</i>. 2011;24(2):119-122. © 2011 The Korean Pain Society, <div class=\"adjustRight\">reproduced with permission."
                                                                               ]
        },
        "references": {
            "row": [
                "Data on File, 1390903. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600."
                                                                                                                                                                                                                                                                                  ]
        }
    },
    {
        "id": "29",
        "title": "J.Q.",
        "age": "73",
        "file": "patient-029.xml",
        "progType":"Progression",
        "timeValue":2,
        "prog": "&gt;12 Months<sup>*</sup>",
        "siteValue": 1,
        "loc": "Bone",
        "symp": "Mild/Moderate",
        "symptomValue":1,
        "image": { "src": "images/profiles/29.png" },
        "banner": "<b><span>61.0<span class=\"percentage\">%</span></span> of CONFIRM<sup>†</sup> patients had any bone<br/>metastases at baseline.</b><sup>1,‡</sup>",
        "summary": "<ul><li>73 years of age</li><li>Recurrence &gt;12 months after completion of adjuvant therapy</li><li>Bone metastases</li><li>Mild/moderate symptoms</li></ul>",
        "status": {
            "row": [
                "73-year-old woman with a history of breast cancer",
            "Patient had completed 5 years of adjuvant hormonal therapy (HT) (tamoxifen) 16 months ago",
            "Presented with localized, non-radiating pain in center of <br />chest; tenderness on palpation over sternum, normal electrocardiography (EKG)",
            "Bone scan and magnetic resonance imaging (MRI) suggested metastatic disease localized to sternum with 1 lytic lesion",
            "Tamoxifen started and patient progressed 14 months later and experienced a return of chest pain",
            "Patient had prior radiation to chest",
            "ECOG<sup>§</sup> Performance Status: 1"
                ]
        },
        "imaging": {
            "row": [
                "Bone scan and MRI reveal increase in size of lytic lesion in sternum compared to scan 6 months prior",
            "No evidence of other metastatic disease"
                ]
        },
        "testing": {
            "row": [
                "Bone biopsy confirms metastatic disease. Estrogen receptor (ER)+/progesterone receptor (PgR)+, human epidermal growth factor receptor-2 (HER2) negative status, with pathology consistent with primary tumor",
            "Laboratory values:<ul><li class=\"dash\">Elevated cancer antigen CA 27.29: 81 U/mL </li><li class=\"dash\">Normal liver function tests</li></ul>"
                ]
        },
        "footnotes": {
            "row": [
                "<sup>*</sup>Recurrence >12 months after completion of adjuvant hormonal therapy (tamoxifen) and progression<br /><div class=\"adjustRight\">after hormonal therapy (tamoxifen) for advanced disease.</div>",
            "<sup>†</sup><b><span style=\"font-family: arial; font-weight: bold;\">CO</span></b>mpariso<b>N</b> of <b>F</b>ASLODEX <b>I</b>n <b>R</b>ecurrent or <b>M</b>etastatic Breast Cancer.<sup>2</sup><br>",
            "<sup>‡</sup>Total number of patients=736. Patients with multiple lesions in the same site are<br><div class=\"adjustRight\">counted only once in that site.<sup>1</sup></div>",
            "<sup>§</sup>Eastern Cooperative Oncology Group.<br>"
                ]
        },
        "references": {
            "row": [
                "Data on File, 1390903. AstraZeneca Pharmaceuticals LP.",
            "Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant <br />250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced <br />breast cancer. <i>J Clin Oncol.</i> 2010;28(30):4594-4600."
                                                                                                                                                                                                                                                                                  ]
        }
    }
    ]
}
